Press Releases

BioIVT Introduces New Products and Services to Improve Safety, Efficacy and Toxicity Testing for Skin Care Products, Cosmetics and Topical Medications

By Lauren Vagnone | November 27, 2017

Westbury, NY –  BioIVT, a leading provider of biospecimens and related services, today announced that it is launching a new line of products and services to improve safety, efficacy and toxicity testing for skin care products, cosmetics and topical medications.

“As the demand for personal skin care products increases – whether they are applied for anti-aging, hydration, wound healing or UV protection purposes – so does the need for better safety, efficacy and toxicity testing systems. The same holds true for new cosmetics and topical medications,” said Dr. Christopher Black, senior vice president of ADME-Tox at BioIVT. “At BioIVT, we are endeavoring to provide researchers in those fields with biological systems that allow them to more clearly understand the disposition of topical applications and their effects on normal and disease-affected skin.”…
Read more

BioIVT to Host Webinar on the Impact of New FDA Draft Guidance on In Vitro Drug-Drug Interaction (DDI) Studies

By Lauren Vagnone | November 27, 2017

Westbury, NY –  BioIVT, a leading provider of biospecimens and related services, today announced that it will host a one-hour webinar entitled: “The New FDA Draft Guidance on In Vitro DDI Studies: How Will It Impact You?” at 11 a.m. ET on Nov. 29. Toxicology experts Dr. Andrew Parkinson, CEO of XPD Consulting, and Dr. Ron Laethem, lead, in vitro services at Qualyst Transporter Solutions, a BioIVT company, will discuss how the guidance has changed and how it will impact drug development strategies…
Read more

BioIVT to Present Advances in Immunohistochemistry at AAPS Annual Meeting

By Lauren Vagnone | November 7, 2017

BioIVT will also showcase its expanded research services resulting from its Qualyst Transporter Solutions and Asterand Bioscience™ acquisitions earlier this year

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it will be presenting and exhibiting at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. This conference will be held from Nov. 12-15 at the San Diego Convention Center in San Diego, CA.

“BioIVT is proud to support AAPS, share our knowledge and experience, and help to support the next generation of pharmaceutical scientists. High content immunohistochemistry (IHC) is an exciting and rapidly-evolving field, and at BioIVT we are expanding our expertise and services to ensure that we continue to meet researchers’ growing needs,” said Dr. Amanda Woodrooffe, BioIVT vice president and general manager, UK…
Read more

BioIVT Expands Its Support for Precision Medicine Researchers

By Lauren Vagnone | October 24, 2017

BioIVT is sponsoring the Powering Precision Health Summit 2017 and showcasing its precision medicine product and services portfolio

Westbury, NY –  BioIVT, a leading provider of biospecimens and related services, today announced that it is sponsoring the Powering Precision Health Summit (PPHS) 2017. This conference will bring together leaders in biomarker research and translational medicine to present the latest advances in their disciplines. It will be held from Oct. 24-25 at the Charles Hotel in Cambridge, MA…
Read more

BioIVT Expands its Support of the Annual North American ISSX Meeting; Highlights Advances in Drug Metabolism and Toxicology Research

By Lauren Vagnone | September 21, 2017

BioIVT is sponsoring two symposia, giving several presentations, and exhibiting at this year’s conference

Westbury, NY –  BioIVT, a leading provider of biospecimens and related services, today announced that it is increasing its support of the annual North American International Society for the Study of Xenobiotics (ISSX) Meeting. BioIVT will be sponsoring two symposia, giving several presentations, and exhibiting at this year’s conference. This event will be held from Sept. 24-28 at the Rhode Island Convention Center in Providence, RI…
Read more

BioIVT Acquires Qualyst Transporter Solutions, Enables Researchers to Predict New Drug Candidates’ Impact on the Liver

By Lauren Vagnone | September 7, 2017

Acquisition will expand BioIVT’s ADME-Toxicology product line

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it has acquired Qualyst Transporter Solutions, LLC. Qualyst provides in vitro hepatic models and services that predict the effect of drugs and other compounds on the human liver in the pharmaceutical, chemical, consumer products, and cosmetics industries.

Qualyst uses a unique cell-based testing approach to predict compound clearance, drug-drug interactions, and toxicity in the human liver. In fact, it established the industry standard for hepatocytes; its Transporter Certified™ hepatocyte program ensures that cells, under defined culture conditions, maintain physiologic transporter uptake and efflux levels which are critical for normal function…
Read more

BioreclamationIVT Acquires Biospecimen and Research Services Provider Asterand Bioscience

By Lauren Vagnone | August 10, 2017

Acquisition broadens BioreclamationIVT’s disease-state biospecimen capabilities, particularly in oncology, and expands its scientific service offerings for diagnostic and drug development researchers

Westbury, NY – BioreclamationIVT, a leading provider of biospecimens and related services, today announced that it has acquired Asterand Bioscience™, a global provider of high quality, well-characterized human tissue and research solutions with a focus on the oncology market. Asterand Bioscience advances drug research by accelerating target identification and biomarker validation, and improving drug candidate selection to increase the likelihood of clinical success. ”…
Read more

BioreclamationIVT Expands Biological Sample Portfolio to Support Drug, Diagnostic and Vaccine Development for Five Additional Infectious Diseases

By Lauren Vagnone | July 31, 2017

The company now offers HIV-1, HIV-2, dengue, zika and malaria blood-derived biological samples to advance drug, diagnostic and vaccine development against those devastating diseases

Westbury, NY – BioreclamationIVT, a leading provider of biospecimens and related services, today announced that it has expanded its infectious disease-state portfolio to include frozen whole blood, plasma and serum samples from patients with HIV-1, HIV-2, dengue, zika and malaria infection. The HIV-1 collection includes samples from pediatric patients and pregnant women.

“We are pleased to be able to provide biopharmaceutical companies with these vitally important biological samples that their researchers need to create diagnostics and develop therapeutic drugs and vaccines against these dreadful diseases. These biological samples are very hard to source because some of the diseases are seen predominantly in donors from underdeveloped countries,” said BioreclamationIVT Senior Vice President, Clinical Operations Clifford M. Raynor. …
Read more

BioreclamationIVT Appoints Vice President of Global Quality and Compliance

By Lauren Vagnone | July 26, 2017

Westbury, NY – BioreclamationIVT, a leading provider of biospecimens and related services, today announced that it has appointed Karen Sasse to the newly-created position of vice president of global quality and compliance. Ms. Sasse will be responsible for the company’s quality assurance and quality control activities worldwide.

“We are delighted to have an operations professional of Karen’s caliber join our growing team. Her drive, strong project management skills, and superlative attention to detail will help to ensure that our biological products continue to exceed our customers’ highest expectations,” said BioreclamationIVT Chief Executive Officer Jeff Gatz. …
Read more

BioreclamationIVT and Qualyst Partner to Market Transporter Certified™ Hepatocytes

By Lauren Vagnone | June 22, 2017

Westbury, NY – BioreclamationIVT, a leading provider of biospecimens and related services, today announced that it is partnering with Qualyst Transporter Solutions, LLC (Qualyst) to market Transporter Certified™ cryopreserved human hepatocytes.

Transporter Certified is an industry standard that ensures hepatocytes have physiologic transporter function, metabolic competence and appropriate regulatory pathways under conditions Qualyst has defined. In sandwich culture, the intracellular concentrations in Transporter Certified hepatocytes reflect physiologic conditions because the hepatocytes express functioning uptake and efflux transporters and develop bile pockets similar to bile canaliculi. …
Read more